Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis

Prostate

Volumn 73, Issue 1, 2013, Pages 71-82

  Krishnan, Bhavani ^a   Smith, Thomas L ^a   Dubey, Purnima ^a   Zapadka, Michael E ^a   Torti, Frank M ^a   Willingham, Mark C ^a   Tallant, E Ann ^a   Gallagher, Patricia E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin (1 7); metastatic prostate cancer; osteoclasts; vascular endothelial growth factor

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANGIOGENESIS INHIBITOR; ANGIOTENSIN[1-7]; ANTIMETASTATIC AGENT; EOSIN; HEMATOXYLIN; VASCULOTROPIN;

ADVANCED CANCER; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BONE MARROW CELL; BONE METASTASIS; BREAST CANCER; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFICACY; HISTOCHEMISTRY; HUMAN; HUMAN CELL; LUNG CANCER; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TIBIA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ADENOCARCINOMA; AGED; ANGIOTENSIN I; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, NUDE; MICE, SCID; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOCLASTS; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870549247     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22542     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Rove KO, Flaig TW,. A renaissance in the medical treatment of advanced prostate cancer. Oncology (Williston Park) 2010; 24: 1308-1318.
3. Foley R, Marignol L, Keane JP, Lynch TH, Hollywood D,. Androgen hypersensitivity in prostate cancer: Molecular perspectives on androgen deprivation therapy strategies. Prostate 2011; 71: 550-557.
4. Molina A, Belldegrun A,. Novel therapeutic strategies for castration resistant prostate cancer: Inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011; 185: 787-794.
5. Macfarlane RJ, Chi KN,. Research in castration-resistant prostate cancer: What does the future hold? Curr Oncol 2010; 17 (Suppl. 2): S80-S86.
6. Morrissey C, Vessella RL,. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 2007; 101: 873-886. (Pubitemid 47040869)
7. Fitzpatrick JM,. The application of nanotechnology for the treatment of metastatic prostate cancer. BJU Int 2009; 104: i.
8. Msaouel P, Pissimissis N, Halapas A, Koutsilieris M,. Mechanisms of bone metastasis in prostate cancer: Clinical implications. Best Pract Res Clin Endocrinol Metab 2008; 22: 341-355. (Pubitemid 351611957)
9. Storey JA, Torti FM,. Bone metastases in prostate cancer: A targeted approach. Curr Opin Oncol 2007; 19: 254-258. (Pubitemid 46597486)
10. American Cancer Society. Facts and figures 2010. Atlanta, GA: American Cancer Society; 2010. pp. 22-37.
11. Macfarlane RJ, Chi KN,. Novel targeted therapies for prostate cancer. Urol Clin North Am 2010; 37: 105-119, Table.
12. Body JJ,. New developments for treatment and prevention of bone metastases. Curr Opin Oncol 2011; 23: 338-342.
13. Neville-Webbe HL, Holen I, Coleman RE,. The anti-tumour activity of bisphosphonates. Cancer Treat Rev 2002; 28: 305-319. (Pubitemid 36054539)
14. Gallagher PE, Tallant EA,. Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 2004; 25: 2045-2052. (Pubitemid 39534840)
15. Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA, Gallagher PE,. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res 2007; 67: 2809-2815. (Pubitemid 46548970)
16. Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA,. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 2009; 8: 1676-1683.
17. Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE,. Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res 2010; 70: 8319-8328.
18. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM,. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res 2009; 15: 7398-7404.
19. Lowry OH, Rosebrough MJ, Farr AL, Randall RJ,. Protein measurement with the Folin-Phenol reagent. J Biol Chem 1951; 193: 265-275.
20. Brosnihan KB, Neves LA, Joyner J, Averill DB, Chappell MC, Sarao R, Penninger J, Ferrario CM,. Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension 2003; 42: 749-753. (Pubitemid 37237320)
21. Erlebacher A, Derynck R,. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 1996; 132: 195-210.
22. Coenegrachts L, Maes C, Torrekens S, Van LR, Mazzone M, Guise TA, Bouillon R, Stassen JM, Carmeliet P, Carmeliet G,. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res 2010; 70: 6537-6547.
23. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, Logothetis CJ, Lin SH,. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res 2008; 6: 1259-1267.
24. Chappell MC, Pirro NT, Sykes A, Ferrario CM,. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 1998; 31: 362-367.
25. Guise T,. Examining the metastatic niche: Targeting the microenvironment. Semin Oncol 2010; 37 (Suppl. 2): S2-S14.
26. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massague J,. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16: 67-78.
27. Roodman GD,. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
28. Machado RD, Santos RA, Andrade SP,. Opposing actions of angiotensins on angiogenesis. Life Sci 2000; 66: 67-76. (Pubitemid 30025450)
29. Casimiro S, Guise TA, Chirgwin J,. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009; 310: 71-81.
30. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D,. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010; 116: 1406-1418.
31. Sterling JA, Edwards JR, Martin TJ, Mundy GR,. Advances in the biology of bone metastasis: How the skeleton affects tumor behavior. Bone 2011; 48: 6-15.
32. Street J, Lenehan B,. Vascular endothelial growth factor regulates osteoblast survivalâEvidence for an autocrine feedback mechanism. J Orthop Surg Res 2009; 4: 19.
33. Mayer H, Bertram H, Lindenmaier W, Korff T, Weber H, Weich H,. Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: Autocrine and paracrine role on osteoblastic and endothelial differentiation. J Cell Biochem 2005; 95: 827-839. (Pubitemid 41420169)
34. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET,. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004; 64: 994-999. (Pubitemid 38176902)
35. Matsumoto Y, Okada Y, Fukushi J, Kamura S, Fujiwara T, Iida K, Koga M, Matsuda S, Harimaya K, Sakamoto A, Iwamoto Y,. Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone. J Orthop Surg Res 2010; 5: 85.
36. Niida S, Kondo T, Hiratsuka S, Hayashi S, Amizuka N, Noda T, Ikeda K, Shibuya M,. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci USA 2005; 102: 14016-14021. (Pubitemid 41377695)
37. Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, Keller ET,. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 2005; 65: 10921-10929. (Pubitemid 41713360)
38. Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone N,. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res 2011; 17: 2328-2338.
39. Haggstrom S, Bergh A, Damber JE,. Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma. Prostate 2000; 45: 42-50.
40. Yang Q, McHugh KP, Patntirapong S, Gu X, Wunderlich L, Hauschka PV,. VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol 2008; 27: 589-599.
41. Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Nishikawa S, Tanne K, Maeda N, Nishikawa S, Kodama H,. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999; 190: 293-298. (Pubitemid 29354921)